Last year I joined an unparalleled group of domain experts to help author the HIMSS-produced book Blockchain in Healthcare: Innovations that Empower Patients, Connect Professionals and Improve Care. I was honored to be invited to contribute the chapter on blockchain and pharmacy alongside my colleague Beth Breeden from Lipscomb University College of Pharmacy & Health Sciences in Nashville, TN. The print edition of the book debuted at the HIMSS19 conference in Orlando, FL, and the e-version has since been released on Amazon Kindle and Apple Books.
We divided our chapter into four subsections:
- Healthcare Financials (which is where many of the earliest wins are coming in the space using Hyperledger builds)
- Pharmaceutical Supply Chain (which we started exploring in 2015, and still holds great promise – as does the broader health supply chain and emerging cannabis market)
- Clinical Trials (which was a conversation that we began during a Precision Medicine Workshop at the White House in 2016), and
- Social Good (which features some of the projects I am most excited about sharing including Solaster and RemediChain)
This chapter also details a few use cases including an interesting, albeit early, proposed approach by ConsenSys on using distributed ledger technology (DLT) for combating a few elements of the opioid crisis.
If you are interested in the intersection of of healthcare and blockchain/DLT, I can’t think of a better place to start than this text!
Distributed:Health 2016 was the first ever healthcare-focused blockchain conference in the world. It was held in the healthcare capital of the United States – Nashville, TN. It was a terrific event and helped birth ideas, collaborations, and companies. In 2017, Distributed:Health was back in Nashville with conversations about much more mature efforts in the space. By the end of the 2017 conference, a common refrain was: last year people asked what blockchain was, but this year people are talking about what they are doing. I was fortunate to be part of one of those main stage conversations centered around the use of blockchain for clinical research organizations (CROs) and data sharing. I was joined by the luminaries listed on the title slide below, which represented a spectrum ranging from evangelists to skeptics.
Over the past few years my exploration of blockchain for healthcare has been an interesting journey. As has everyone I would imagine, I have received a lot of questions about blockchain – particularly in the last 12 months. They range from generalist inquiries to consulting requests. Often it is about how I became involved. To that end, I have added a brief timeline of my roles and work in in this arena, which can be found here.
On a recent trip to Indianapolis I was able to take part in the annual meeting of the American Association of Diabetes Educators (AADE) and share a bit about the digital health space as it relates to the role of diabetes educators and patient care.
A summary of my presentation published in The American Journal of Managed Care Evidence-Based Diabetes Management, written by Mary Caffrey as part of her coverage of AADE appears below and can be accessed in full here.
AADE 2017 was an extremely well-organized conference that made great strides in the digital health arena this year, highlighted by Chris Bergstrom’s session “Let’s Get Digital”.
The White House Office of Science Technology and Policy and Stanford Medicine X co-created a special event to “…focus on engaging participants as partners in research, a core principle of the President’s Precision Medicine Initiative.” The event was hosted at the White House and captured the spirit of Everyone Included as it was comprised of a diverse group of patients, researchers, clinicians, designers, and technologists, as well as experts in law, policy, and citizen science. As can be imagined, it was quite a humbling experience to be invited to go to the White House and take part in this august gathering.
Reflecting the co-creation of the event, it was opened in concert by OSTP’s @ClaudiaWilliams (above) and Med X’s @LarryChu (below) followed by addresses by White House OSTP leadership including Chief Data Scientist DJ Patil, Precision Medicine Initiative Project Manager Stephanie Devaney, and later US Chief Technology Officer Megan Smith.
Johns Hopkins – Sibley Innovation Hub’s @NickDawson (below) set the tone by brandishing post it notes. He encouraged everyone to use these sticky notes as the tools of a designer and the Stanford Medicine X’s Brainstorming Tips throughout the Workshop to develop questions and aims tied to partnering with participants for research with an eye towards the Precision Medicine Initiative (PMI).
My impression was that the use of the broader term “participants” rather than the narrower category of “patients” was a PMI-influenced reflection of the roles to be played in research by people who self-identify as “in good health” or “well” or those who are focused on maintaining health rather than managing an acute or chronic health challenge.
Claudia Williams also announced that during the event the
Robert’s Rules of Order Chatham House Rule would be in effect.
The Infusion Nurses Society asked me to speak about the use of social media and patient education at their INS Annual Meeting (#INS2016). This year INS Annual was held in Ft. Lauderdale, FL. I have not had many opportunities to return to the Sunshine State since I relocated to Nashville two years ago, so I was looking forward to this conference on several fronts.
The presentation ended up being a little more broadly based on social media in health care to account for the pretty wide mix of social media users in the audience. The full deck is embedded below; presentation subtopics were: social media platforms & usage, educating our patients about social media identities, health care education and behavior change for patients, social media research, and #socialgood.
I was able to attend some of the other sessions and speak with attendees and presenters. Infusion nursing is not an area I have expertise in, so essentially everything I saw and heard was a good learning experience. I also learned a modest, but thoughtful thank you gift with a handwritten note for speakers still means a lot. Nicely done INS!
Over the last two years I have been fortunate to work with some real leaders in pharmacy informatics education. One of the most accomplished pioneers in this realm is Dr. Beth Breeden, who is the Director of the Master of Health Care Informatics (MHCI) program at the Lipscomb University College of Pharmacy and Health Sciences in Nashville, TN. Pharmacy students at our University have a rare set of opportunities in informatics education, including a dual pharmacy-informatics program that is the second of its kind in the country. Pharmacy students can choose to concurrently complete a dual PharmD+MHCI or PharmD+Certificate in HCI. We also offer both summer internships and a specialty residency in partnership with Vanderbilt University focused on pharmacy informatics as well as related experiential and research opportunities to our students. It doesn’t hurt that Nashville has evolved into the health care capital of the country. But creating these types of health care informatics opportunities for pharmacy students is a challenge nationally for pharmacy and other health care educators, which is why the article described below was written. Hopefully the framework presented and specific examples described help educators working in even the most resource-challenged environs develop informatics opportunities for their students.
Development and implementation of a multitiered health informatics curriculum in a college of pharmacy.
Journal of the American Medical Informatics Association. 2016 Apr 27. pii: ocw023. doi: 10.1093/jamia/ocw023.
Breeden EA, Clauson KA.
Standards requiring education in informatics in pharmacy curricula were introduced in the last 10 years by the Accreditation Council for Pharmacy Education. Mirroring difficulties faced by other health professions educators, implementation of these requirements remains fragmented and somewhat limited across colleges of pharmacy in the US. Clinical practice and workforce metrics underline a pronounced need for clinicians with varying competencies in health informatics. In response to these challenges, a multitiered health informatics curriculum was developed and implemented at a college of pharmacy in the Southeast. The multitiered approach is structured to ensure that graduating pharmacists possess core competencies in health informatics, while providing specialized and advanced training opportunities for pharmacy students, health professions students, and working professionals interested in a career path in informatics. The approach described herein offers institutions, administrators, faculty, residents, and students an adaptable model for selected or comprehensive adoption and integration of a multitiered health informatics curriculum.
While not quite Fantasy Island, I recently enjoyed a trip to Hilton Head Island, South Carolina where I stayed…at a Marriott. Turns out the island is named after Captain William Hilton. No relation to the Marriott International, Inc (formerly Hot Shoppes!) folks. I was there for the 2015 Annual Meeting of the South Carolina Society of Health-System Pharmacists to speak about the emerging area of wearable technology in pharmacy. It was a nice, tightly run conference with good speakers and active attendees.
From the one-of-these-things-is-not-like-the-other research file, this gem of a study was heavily influenced by the psych titans who I was fortunate enough to collaborate with. I learned quite a bit, including the term cosmetic psychopharmacology. I rationalize this occasional stream-adrift type of research with the findings of a 2015 MIT Sloan Management Review piece which concluded that professionals with diverse (Twitter) networks who get out of their comfort zones and gain exposure to different processes were more likely to surface innovative ideas. That’s my story. I am sticking to it.
Cognitive and performance enhancing medication use to improve performance in poker.
Journal of Gambling Studies. 2015 Oct 8.
Caballero J, Ownby RL, Rey JA, Clauson KA.
Use of neuroenhancers has been studied in groups ranging from students to surgeons; however, use of cognitive and performance enhancing medications (CPEMs) to improve performance in poker has remained largely overlooked. To assess the use of CPEMs to improve poker performance, a survey of poker players was conducted. Participants were recruited via Internet poker forums; 198 completed the online survey. Approximately 28 % of respondents used prescription CPEMs, with the most commonly used including: amphetamine/dextroamphetamine (62 %), benzodiazepines (20 %), and methylphenidate (20 %). CPEMs were used in poker to focus (73 %), calm nerves (11 %), and stay awake (11 %). Caffeine (71 %), as well as conventionally counter-intuitive substances like marijuana (35 %) and alcohol (30 %) were also reported to enhance poker performance. Non-users of CPEMs were dissuaded from use due to not knowing where to get them (29 %), apprehension about trying them (26 %), and legal or ethical concerns (16 %). Respondents most frequently acquired CPEMs via friends/fellow poker players (52 %), or prescription from physician (38 %). Additionally, greater use of CPEMs was associated with living outside the United States (p = 0.042), prior use of prescription medications for improving non-poker related performance (p < 0.001), and amateur and semi-professional player status (p = 0.035). Unmonitored use of pharmacologically active agents and their methods of acquisition highlight safety concerns in this cohort of poker players, especially among non-professional players. The current state of guidance from national organizations on CPEM use in healthy individuals could impact prescribing patterns.
The summary and book chapter below represent our contributions to this text. The topic remains an area I have great enthusiasm about and high hopes for, when executed well.
Irrational use of medications is a global challenge, with the World Health Organization (WHO) estimating that “more than half of all medicines are prescribed, dispensed, or sold inappropriately”. This situation is exacerbated by half of all patients not taking their medications as intended, with non-adherence rates in disorders like schizophrenia reaching over 70%. Medication non-adherence and polypharmacy (i.e., use of multiple medications) are massive barriers to optimal medication management and are the source of substantial health and financial costs. Mobile health (mHealth) offers myriad methods to address these challenges, ranging from simple text message reminder systems to ecological momentary interventions (EMIs) to leveraging interface versatility for eHealth literacy solutions. In this chapter, current scientific evidence will be used to explore the role of mHealth in enhancing pharmacy-related outcomes in varying healthcare settings and diverse populations. Current and future developments in mHealth will be explored through the lens of select disease states and patient populations.
A gentle street poet named Earl Simmons once penned the words, “X Gonna Give It To Ya”. I can’t remember the next line of the stanza, but I think it may have been, “If You Let it”. He may very well have been talking about Stanford Medicine X, because you kind of have to be open to what it has to offer. But if you are, it will deliver quite an experience.
As usual, #MedX started well before the conference proper with the pre-conference which generated an outpouring of tweets and other activities leading up to its kickoff this year and throughout the conference. If there is any doubt, the fine folks at Symplur have put that question to bed.
From the pre-conference, there was a high-utility tweetstream for anyone interested in clinical trial design, particularly those seeking ways to integrate the patient. From afar, it appeared the workshop was very effective in introducing epatients to the complexities and headaches of clinical trial design and execution AND in introducing researchers to what epatients really care and think about with clinical trials.